Lumateperon, czyli nowy rozdział w terapii schizofrenii

Ross CA, Margolis RL. Research domain criteria: Toward future psychiatric nosology. Dialogues Clin Neurosci. 2019;21(3):249-255.

Shorter E. A Historical Dictionary of Psychiatry. New York, NY: Oxford University Press; 2005.

Scull A. Madness in Civilization: A Cultural History of Insanity. Princeton, NJ: Princeton University Press; 2015.

López-Muñoz F, Alamo C. Neurobiological background for the development of new drugs in schizophrenia. Clin Neuropharmacol. 2011;34(4):151–168.

Lieberman JA, Davis RE, Correll CU, et al. ITI-007: a novel and multimodal treatment for schizophrenia. Neuropsychopharmacology. 2016;41(4):1011–1021.

Nasrallah HA. The role of lumateperone in treating schizophrenia. Drugs Today (Barc). 2020;56(1):11–18.

Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.

Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86-97.

Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187-193.

Jablensky A. The diagnostic concept of schizophrenia: its history, evolution, and future prospects. Dialogues Clin Neurosci. 2010;12(3):271-287.

Tsuang MT, Stone WS, Faraone SV. Genes, environment and schizophrenia. Br J Psychiatry Suppl. 2001;40:s18-s24.

Sullivan PF, Daly MJ, O’Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2018;19(8):537–551.

Cardno AG, Gottesman II. Genetic aspects of schizophrenia. Handb Clin Neurol. 2012;106:139-159.

Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157(1):16-25.

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophr Bull. 2009;35(3):549-562.

Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006;26(4-6):365-384.

Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;212:87–124.

Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3-10.

Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.

Green MF, Horan WP, Lee J. Social cognition in schizophrenia. Nat Rev Neurosci. 2015;16(10):620–631.

McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry. 2010;55(8):486-497.

Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107-120.

Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 5. Treatment and prevention. Schizophr Res. 2010;122(1-3):1–23.

Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–253.

Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4_suppl):81–90.

Kuipers E, Bebbington P, Dunn G, et al. Influence of carer expressed emotion and affect on relapse in non-affective psychosis. Br J Psychiatry. 2006;188:173–179.

Charlson FJ, Ferrari AJ, Santomauro DF, et al. Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195–1203.

Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279–293.

Wysokiński A. Functional recovery – a modern objective for schizophrenia treatment. Psychiatria Spersonalizowana / Personalized Psychiatry. 2022;1(1):11-15.

Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. American Journal of Psychiatry. 2005;162(3):441-449. doi:10.1176/appi.ajp.162.3.441

Gründer G, Bauknecht P, Klingberg S, et al. Treatment Goals for Patients with Schizophrenia — A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry. 2020;54(02):53-59. doi:10.1055/a-1298-454

Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophrenia Bulletin. 2009;35(2):347-361. doi:10.1093/schbul/sbn177

Ganguly P, Soliman A, Moustafa AA. Holistic management of schizophrenia symptoms using pharmacological and non-pharmacological treatment. Frontiers in Public Health. 2018;6. doi:10.3389/fpubh.2018.00166

Cempa K, Jurys T, Kluczyński S, Andreew M. Physical activity as a therapeutic method for non-pharmacological treatment of schizophrenia: A systematic literature review. Psychiatria Polska. 2022;56(4):837-859. doi:10.12740/pp/140053

Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. https://pmc.ncbi.nlm.nih.gov/articles/PMC4159061/. Published September 1, 2014.

Azargoonjahromi A. Current findings and potential mechanisms of KARXT (Xanomeline–Trospium) in schizophrenia treatment. Clinical Drug Investigation. 2024;44(7):471-493. doi:10.1007/s40261-024-01377-9

Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2019;172:107704. doi:10.1016/j.neuropharm.2019.107704

Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Therapeutics and Clinical Risk Management. 2017;Volume 13:757-777. doi:10.2147/tcrm.s117321

Ali T, Sisay M, Tariku M, Mekuria AN, Desalew A. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. PLoS ONE. 2021;16(9):e0257129. doi:10.1371/journal.pone.0257129

Verster JC, Tzschentke TM, O’Malley K, et al. First-Generation antipsychotics. In: Springer eBooks. ; 2010:534-536. doi:10.1007/978-3-540-68706-1_251

Olszanecki R, Wołkow P, Jawień J. Farmakologia. mechanizmy - leki - farmakoterapia oparta na faktach. tom 1. PZWL Wydawnictwo Lekarskie; 2023.

Sheikhi N, Bahraminejad M, Saeedi M, Mirfazli SS. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022. European Journal of Medicinal Chemistry. 2023;260:115758. doi:10.1016/j.ejmech.2023.115758

Chong JWX, Tan EHJ, Chong CE, Ng Y, Wijesinghe R. Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Mental Health Clinician. 2016;6(4):178-184. doi:10.9740/mhc.2016.07.178

Puranen A, Koponen M, Lähteenvuo M, Tanskanen A, Tiihonen J, Taipale H. Real‐world effectiveness of mood stabilizer use in schizophrenia. Acta Psychiatrica Scandinavica. 2022;147(3):257-266. doi:10.1111/acps.13498

Nayak R, Rosh I, Kustanovich I, Stern S. Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems. International Journal of Molecular Sciences. 2021;22(17):9315. doi:10.3390/ijms22179315

Rummel C, Kissling W, Leucht S. Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. Schizophrenia Research. 2005;80(1):85-97. doi:10.1016/j.schres.2005.07.035

Howells FM, Kingdon DG, Baldwin DS. Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. Human Psychopharmacology Clinical and Experimental. 2017;32(5). doi:10.1002/hup.2628

Salahuddin NH, Schütz A, Pitschel-Walz G, et al. Psychological and psychosocial interventions for treatment-resistant schizophrenia: a systematic review and network meta-analysis. The Lancet Psychiatry. 2024;11(7):545-553. doi:10.1016/s2215-0366(24)00136-6

Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. The Lancet. 2022;399(10323):473-486. doi:10.1016/s0140-6736(21)01730-x

Xu F, Zhang H. The application of cognitive behavioral therapy in patients with schizophrenia: A review. Medicine. 2023;102(32):e34827. doi:10.1097/md.0000000000034827

Kart A, Özdel K, Türkçapar MH. COGNITIVE BEHAVIORAL THERAPY FOR SCHIZOPHRENIA. Nöro Psikiyatri Arşivi. January 2021. doi:10.29399/npa.27418

Budiono W, Kantono K, Kristianto FC, Avanti C, Herawati F. Psychoeducation Improved Illness Perception and Expressed Emotion of Family Caregivers of Patients with Schizophrenia. International Journal of Environmental Research and Public Health. 2021;18(14):7522. doi:10.3390/ijerph18147522

Wojtasik-Bakalarz K, Siwek M. New antipsychotic medication. Pharmacotherapy in Psychiatry and Neurology. 2023;39(1):19-38. doi:10.5114/fpn.2022.124608

Longo G, Cicolini A, Orsolini L, Volpe U. The novel Antipsychotic lumateperone (ITI-007) in the Treatment of Schizophrenia: A Systematic review. Brain Sciences. 2023;13(12):1641. doi:10.3390/brainsci13121641

Kaczmarek A, Szymajda W, Dettlaff K. Lumateperone in the treatment of psychiatric disorders – a review of the literature. Pharmacotherapy in Psychiatry and Neurology. 2023;39(1):39-52. doi:10.5114/fpn.2023.127423

Sowa-Kućma M, Pańczyszyn-Trzewik P, Jaeschke RR. Exploring the pharmacological and clinical features of Lumateperone: a promising novel antipsychotic. International Journal of Molecular Sciences. 2024;25(24):13289. doi:10.3390/ijms252413289

https://www.sigmaaldrich.com/PL/pl/product/sigma/sml2866?srsltid=AfmBOorPofqdaEEt9KMCFB56cvXh67GvWc5DPF9JAh2VYc4IJuOO89kh

Cooper D, Gupta V. Lumateperone. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK560844/. Published July 17, 2023.

Fountoulakis KN, Tohen M, Zarate CA. Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data. European Neuropsychopharmacology. 2024;81:1-9. doi:10.1016/j.euroneuro.2024.01.002

Jawad MY, Alnefeesi Y, Ceban F, et al. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review. Curr Psychiatry Rep. 2022;24(8):359-368. doi:10.1007/s11920-022-01344-1

Maini K, Hollier JW, Gould H, et al. Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia. Health Psychology Research. 2021;9(1). doi:10.52965/001c.24932

Vyas P, Hwang BJ, Brašić JR. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy. 2019;21(2):139-145. doi:10.1080/14656566.2019.1695778

Yıldız M, İncedere A, Gürcan MB, Osman E. Brief Clinical Assessment Scale for Schizophrenia (BCAS-S): development, validity, and reliability study. Archives of Neuropsychiatry. Published online 2021. doi:10.29399/npa.27592

Syed AB, Brašić JR. The role of lumateperone in the treatment of schizophrenia. Therapeutic Advances in Psychopharmacology. 2021;11. doi:10.1177/20451253211034019

Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. Biological Psychiatry. 2016;79(12):952-961. doi:10.1016/j.biopsych.2015.08.026

Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Review of Neurotherapeutics. 2016;16(6):601-614. doi:10.1080/14737175.2016.1174577

Mazza M, Marano G, Traversi G, Sani G, Janiri L. Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders. CNSNDDT. 2020;19(4):243-247. doi:10.2174/1871527319666200601145653

Ahmad SR, Zeyaullah M, AlShahrani AM, et al. Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia. Bioimpacts. Published online September 9, 2024. doi:10.34172/bi.30259

DePietro T. Lumateperone: A Truly Innovative Antipsychotic Medication? AJP Residents’ Journal. 2023;18(3):18-20. doi:10.1176/appi.ajp-rj.2023.180306

https://www.drugs.com/price-guide/caplyta